Currently, the CTONG0803 study and the BRAIN study have confirmed that icotinib is superior to radiotherapy in the control of intracranial lesions in NSCLC patients with EGFR-positive multiple brain metastases (15, 16). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.